BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 34059198)

  • 21. First successful use of eltrombopag before surgery in a child with MYH9-related thrombocytopenia.
    Favier R; Feriel J; Favier M; Denoyelle F; Martignetti JA
    Pediatrics; 2013 Sep; 132(3):e793-5. PubMed ID: 23940247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eltrombopag (Promacta), a thrombopoietin receptor agonist for the treatment of thrombocytopenia: current and future considerations.
    Serebruany VL; Eisert C; Sabaeva E; Makarov L
    Am J Ther; 2010; 17(1):68-74. PubMed ID: 19451811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Milestones in understanding platelet production: a historical overview.
    Kuter DJ
    Br J Haematol; 2014 Apr; 165(2):248-58. PubMed ID: 24528208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura.
    Nurden AT; Viallard JF; Nurden P
    Lancet; 2009 May; 373(9674):1562-9. PubMed ID: 19324405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eltrombopag for treatment of thrombocytopenia-associated disorders.
    Merli P; Strocchio L; Vinti L; Palumbo G; Locatelli F
    Expert Opin Pharmacother; 2015; 16(14):2243-56. PubMed ID: 26364898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro generation of platelets: Where do we stand?
    Di Buduo CA; Kaplan DL; Balduini A
    Transfus Clin Biol; 2017 Sep; 24(3):273-276. PubMed ID: 28669522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
    Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
    Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.
    Jenkins JM; Williams D; Deng Y; Uhl J; Kitchen V; Collins D; Erickson-Miller CL
    Blood; 2007 Jun; 109(11):4739-41. PubMed ID: 17327409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular insights on Eltrombopag: potential mitogen stimulants, angiogenesis, and therapeutic radioprotectant through TPO-R activation.
    Subbarayan R; Srinivasan D; Shadula Osmania S; Murugan Girija D; Ikhlas S; Srivastav N; Balakrishnan R; Shrestha R; Chauhan A
    Platelets; 2024 Dec; 35(1):2359028. PubMed ID: 38832545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists.
    Makar RS; Zhukov OS; Sahud MA; Kuter DJ
    Am J Hematol; 2013 Dec; 88(12):1041-4. PubMed ID: 23913253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnosis and treatment of
    Rabbolini DJ; Chun Y; Latimer M; Kunishima S; Fixter K; Valecha B; Tan P; Chew LP; Kile BT; Burt R; Radhakrishnan K; Bird R; Ockelford P; Gabrielli S; Chen Q; Stevenson WS; Ward CM; Morel-Kopp MC
    Platelets; 2018 Dec; 29(8):793-800. PubMed ID: 29090586
    [No Abstract]   [Full Text] [Related]  

  • 32. Selective Inhibition of ADAM17 Efficiently Mediates Glycoprotein Ibα Retention During Ex Vivo Generation of Human Induced Pluripotent Stem Cell-Derived Platelets.
    Hirata S; Murata T; Suzuki D; Nakamura S; Jono-Ohnishi R; Hirose H; Sawaguchi A; Nishimura S; Sugimoto N; Eto K
    Stem Cells Transl Med; 2017 Mar; 6(3):720-730. PubMed ID: 28297575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant.
    Bento L; Bastida JM; García-Cadenas I; García-Torres E; Rivera D; Bosch-Vilaseca A; De Miguel C; Martínez-Muñoz ME; Fernández-Avilés F; Roldán E; Chinea A; Yáñez L; Zudaire T; Vaz CP; Espigado I; López J; Valcárcel D; Duarte R; Cabrera R; Herrera C; González-Porras JR; Gutiérrez A; Solano C; Sampol A;
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1825-1831. PubMed ID: 31152794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes.
    Townsley DM; Desmond R; Dunbar CE; Young NS
    Int J Hematol; 2013 Jul; 98(1):48-55. PubMed ID: 23690288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro.
    Iraqi M; Perdomo J; Yan F; Choi PY; Chong BH
    Haematologica; 2015 May; 100(5):623-32. PubMed ID: 25682608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia.
    Haselboeck J; Kaider A; Pabinger I; Panzer S
    Thromb Haemost; 2013 Apr; 109(4):676-83. PubMed ID: 23389750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful treatment of amegakaryocytic thrombocytopenia with eltrombopag in a patient with systemic lupus erythematosus (SLE).
    Cela I; Miller IJ; Katz RS; Rizman A; Shammo JM
    Clin Adv Hematol Oncol; 2010 Nov; 8(11):806-9. PubMed ID: 21326158
    [No Abstract]   [Full Text] [Related]  

  • 38. Enhancing functional platelet release in vivo from in vitro-grown megakaryocytes using small molecule inhibitors.
    Jarocha D; Vo KK; Lyde RB; Hayes V; Camire RM; Poncz M
    Blood Adv; 2018 Mar; 2(6):597-606. PubMed ID: 29545255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platelet bioreactor: accelerated evolution of design and manufacture.
    Thon JN; Dykstra BJ; Beaulieu LM
    Platelets; 2017 Jul; 28(5):472-477. PubMed ID: 28112988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinic, pathogenic mechanisms and drug testing of two inherited thrombocytopenias, ANKRD26-related Thrombocytopenia and MYH9-related diseases.
    Balduini A; Raslova H; Di Buduo CA; Donada A; Ballmaier M; Germeshausen M; Balduini CL
    Eur J Med Genet; 2018 Nov; 61(11):715-722. PubMed ID: 29545013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.